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Abstract: BACKGROUND: Anti-PD1/PD-L1 therapy frequently entails immune-related adverse events
(irAEs) and biomarkers to predict irAEs are lacking. While checkpoint inhibitors have been found to re-
invigorate T-cells, the relevance of autoantibodies remains elusive. OBJECTIVE: Our aim was to explore
whether IgG autoantibodies directed against co-expressed antigens by tumor tissue and healthy skin
correlate with skin irAEs and therapy outcome. METHODS: We measured skin-specific IgG via ELISA in
non-small cell lung cancer (NSCLC) patients, who received anti-PD1/PD-L1 treatment between July 2015
and September 2017 at the Kantonsspital St. Gallen. Sera were sampled at baseline and during therapy
after 8 weeks. RESULTS: Analysis of publicly available tumor expression data revealed that NSCLC and
skin co-express BP180, BP230 and type VII collagen. Of 40 recruited patients, 16 (40%) developed a
skin irAE. Only elevated anti-BP180 IgG at baseline significantly correlated with the development of skin
irAEs (P=.04), therapy response (P=.01) and overall survival (P=.04). LIMITATIONS: The patients
were recruited in a single tertiary care center. CONCLUSIONS: Our data suggest that the level of anti-
BP180 IgG of NSCLC patients at baseline is associated with better therapy response, overall survival
and a higher probability to develop skin irAEs during anti-PD1/PD-L1 treatment.
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Anti-PD1/PD-L1 therapy frequently entails immune-related adverse events (irAEs) 71 
and biomarkers to predict irAEs are lacking. While checkpoint inhibitors have been 72 
found to re-invigorate T-cells, the relevance of autoantibodies remains elusive. 73 
 74 
Objective 75 
Our aim was to explore whether IgG autoantibodies directed against co-expressed 76 




We measured skin-specific IgG via ELISA in non-small cell lung cancer (NSCLC) 81 
patients, who received anti-PD1/PD-L1 treatment between July 2015 and September 82 
2017 at the Kantonsspital St. Gallen. Sera were sampled at baseline and during 83 
therapy after 8 weeks. 84 
 85 
Results 86 
Analysis of publicly available tumor expression data revealed that NSCLC and skin 87 
co-express BP180, BP230 and type VII collagen. Of 40 recruited patients, 16 (40%) 88 
developed a skin irAE. Only elevated anti-BP180 IgG at baseline significantly 89 
correlated with the development of skin irAEs (P=.04), therapy response (P=.01) and 90 






The patients were recruited in a single tertiary care center. 94 
 95 
Conclusions 96 
Our data suggest that the level of anti-BP180 IgG of NSCLC patients at baseline is 97 
associated with better therapy response, overall survival and a higher probability to 98 
develop skin irAEs during anti-PD1/PD-L1 treatment. 99 
 100 
Capsule summary 101 
•  The role of antibodies during anti-PD1/PD-L1 therapy for cancer patients 102 
remains elusive. 103 
•  We found a significant correlation between higher IgG against BP180 antigen 104 
and more skin irAEs, better therapy response and prolonged overall survival 105 
in non-small cell lung cancer patients, suggesting that anti-BP180 IgG levels 106 
may be considered a biomarker. 107 
 108 
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The clinical introduction of immune checkpoint inhibitors (ICIs) has ushered in a new 112 
era in the treatment of metastatic non-small cell lung cancer (NSCLC) and has 113 
significantly prolonged the overall survival (OS) time of NSCLC patients.1 Previous 114 
studies have demonstrated that the Programmed Cell Death Protein-1 (PD1) is 115 
important for maintaining the balance of peripheral tolerance against self-antigens.2 116 
Inhibition of PD1/PD-L1 receptor/ligand pair through use of the antibodies nivolumab, 117 
pembrolizumab and atezolizumab resulted in the development of various immune-118 
related adverse events (irAEs) during therapy. They can affect all organs with 119 
various severity and are a major limitation to their use and effectiveness.3 Severe 120 
irAEs may require therapy interruption and treatment with systemic 121 
immunosuppressants, which potentially compromises the anti-tumor response 122 
elicited by ICIs.4 Among patients treated for NSCLC the most frequent irAEs are 123 
pruritus and skin rashes that typically present a lichenoid inflammation.5 Additionally, 124 
reports of primary manifestations of bullous pemphigoid (BP) during ICI therapy have 125 
emerged and it has been speculated that in this context BP may develop due to a 126 
shared immune response against antigens in cancer cells and healthy skin tissue.6-8 127 
While ICIs are designed to disinhibit T cells, the role of autoantibodies against B-cell 128 
target antigens and their implications for ICI therapy remains largely unknown. We 129 
hypothesize that the expression of an immunogenic B-cell targeted skin antigen in 130 
cancer tissue could trigger the production of autoantibodies that may impact therapy 131 
outcome. Examining our hypothesis required three steps: first, identification of 132 
potential B-cell targets in NSCLC that are also present in healthy skin; second, 133 
assaying autoantibodies directed towards these antigens and third, correlating 134 




Materials and Methods 136 
Gene expression profiling 137 
For estimating the expression of skin antigens in NSCLC tumor tissue, we first 138 
retrieved publicly available RNA-sequencing data of 1.145 NSCLC tissue samples 139 
from The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov). We then 140 
compared the expressed antigens to RNA expression data of healthy reference skin 141 
tissue, provided by the Genotype Tissue Expression project (GTEx, 142 
https://gtexportal.org). We then performed manual filtering via Pubmed 143 
https://www.ncbi.nlm.nih.gov/pubmed) literature searches to select only genes that 144 
have been reported to be autoantibody targets, resulting in a list of top ten B-cell 145 
targets. 146 
 147 
Study design 148 
To collect serum samples we initiated a prospective observational clinical study. The 149 
study was approved by the Ethics committee of Eastern Switzerland (EKOS 16/079) 150 
and conducted in accordance with the Declaration of Helsinki guidelines. We 151 
included 40 patients with NSCLC, who visited the Kantonsspital St. Gallen for 152 
treatment between July 2015 and September 2017. All patients were scheduled to 153 
receive the first cycle of ICI therapy for treatment of NSCLC within two weeks. 154 
Patients, who have been previously treated with an ICI were not admitted into this 155 
study. Written consent was obtained prior to study inclusion and no compensation 156 
was issued for participation. Patients were treated with either the anti-PD1 antibodies 157 
nivolumab (3mg/kg, N = 26 (65%)), pembrolizumab (2mg/kg, N = 12 (30%)) or the 158 
anti-PD-L1 antibody atezolizumab (1200mg, N = 2 (5%)). Peripheral blood was 159 




ICI used. Patient staging was performed in accordance with clinical practice 161 
guidelines.9 Therapy response was radiologically assessed in adherence to the 162 
RECIST 1.1 criteria.10 IrAEs grade 1 were recorded by the physician in charge at 163 
each visit in compliance with the Common Toxicology Criteria for Adverse Events 164 
(5.0). Any irAE grade 2 or above was recorded and additionally assessed a 165 
physician trained in the medical subspecialty of the affected organ.   166 
 167 
Measurement of autoantibodies  168 
Serum IgGs directed to the candidate antigens BP180, BP230 and type VII collagen 169 
were measured by ELISA according to the manufacturer’s instructions (MESACUP 170 
anti-Skin profile kit, MBL, Nagoya, Japan).11 For a second, independent validation 34 171 
of 39 serum samples were available. The validation was conducted using the 172 
following three ELISA kits: for the detection of IgG against BP180 Anti-BP180-173 
NC16A-4X, for detection of IgG against BP230 Anti-BP230CF and for the detection 174 
of IgG against type VII collagen Anti-Collagen Type VII (all Euroimmun AG, Lübeck, 175 
Germany).12-14 176 
 177 
Statistical analysis 178 
R software (version 3.5.0) was used for all statistical analyses. The “survival” 179 
(version 2.43-1) and “survminer” (version 0.4.3) packages in R were used for survival 180 
analysis. The “maxstat” (version 0.7-25) package in R was implemented to identify 181 
optimal cutpoints for IgG levels using the maximally selected log-rank statistics.15 182 
The minimal proportion (‘minprop’ argument) in each group was set to 0.30. Kaplan-183 
Meier plots were generated for OS and patients were categorized into “high” and 184 




association between IgG levels at baseline and OS was examined using the log-rank 186 
test. The Mann-Whitney test was used for calculating the association between IgG 187 
titers and therapy response, irAEs and skin irAEs. OS was calculated with 39 188 
patients, since one patient was lost to follow-up. Response data was available from 189 





RNA sequencing data revealed that three antigens, BP180, BP230 and type VII 192 
collagen are among the top ten B-cell targeted antigens that are overexpressed in 193 
NSCLC and present in healthy skin. Coincidentally, all three antigens are known to 194 
be targets in blistering skin diseases; BP180 and BP230 in BP and type VII collagen 195 
in epidermolysis bullosa acquisita. Among them, BP180 appears to be the most 196 
commonly expressed antigen in NSCLC, as it can be detected in 46.1% (N = 551) of 197 
squamous-cell-carcinoma-type NSCLC and 8.9% (N = 554) of adenocarcinoma-type 198 
NSCLC samples (Figure 1 and Table 1). 199 
Our prospective study cohort included 40 patients (22 (55%) men and 18 (45%) 200 
women). The median age was 67 years. 25 (63%) of patients developed at least one 201 
irAE, of which 16 (40%) affected the skin: 9 (23%) showed skin rash and 7 (18%) 202 
reported pruritus without rash. All cases of skin rash and pruritus were classified as 203 
grades 1 or 2 according to the Common Terminology Criteria for Adverse Events 204 
(CTCAE).16 16 (40%) patients developed other, non-skin related irAEs. Those 205 
included thyroiditis (N = 6 (15%), pneumonitis (N = 4 (10%)), colitis (N = 3 (8%)), 206 
hepatitis (N = 3 (8%)), arthritis (N = 1 (3%)) and nephritis (N = 1 (3%)). 207 
We then measured IgGs in patient sera with specificity to BP180, BP230, and type 208 
VII collagen and correlated their levels with skin irAEs, all irAEs, therapy response 209 
and OS. Anti-BP180 IgG levels significantly correlated with better response (P = .01, 210 
N = 35), prolonged OS (P = .04, N = 39) and the development of skin irAEs (P = .04, 211 
N = 40, see Figure 2, top panel), however not with all irAEs (P = .09, N = 40). 212 
Neither anti-BP230 IgG nor anti-type VII collagen IgG levels showed a correlation 213 
with any outcome (see Figure 2 middle and bottom panels). Outcomes are 214 




21.1 – 1.4), of anti-BP230 IgG 4.8 U/ml (40.5 – 1.7) and of anti-type VII collagen IgG 216 
3.0 U/ml (16.0 – 0.8). The associations with response and OS remained significant in 217 
the ELISA validation test (P = .01 and P = .02, respectively). ELISA on 24 serum 218 
samples that were taken after 8 weeks of therapy showed comparable IgG levels 219 





We investigated whether autoantibodies that target antigens expressed in skin and 222 
NSCLC tissue are associated with outcomes and irAEs of ICI therapy. While the 223 
shared reactivity of T-cells against antigens co-expressed in tumor and healthy skin 224 
has been demonstrated,18 very little is known about the influence of autoantibodies 225 
on therapy outcome. We have previously shown that melanoma-associated 226 
antibodies may serve as potential biomarkers for ICI efficacy in melanoma patients.19 227 
The concept that also irAEs correlate with autoantibodies in PD1- blockade or -228 
deficiency has been reported: Okazaki et al. have demonstrated that PD-1 deficient 229 
mice develop dilated cardiomyopathy due to autoantibodies directed against cardiac 230 
troponin I.20 Das et al. were able to show that early B-cell changes during ICI therapy 231 
are associated with increased autoimmunity.21 Most recently, Toi et al. reported that 232 
certain pre-existing autoantibodies are associated with better ICI therapy outcome 233 
and more irAEs.22 However, no single autoantibody was identified that could be 234 
associated with both at the same time, a better outcome and an associated organ-235 
specific irAE. Using our 2-step approach, first identifying antigens with a shared 236 
tumor and skin expression and then measuring them with clinically validated 237 
diagnostic ELISA, led to the discovery of anti-BP180 IgG as a single marker for 238 
better therapy response, longer OS and the development of skin irAEs. Elevated 239 
serum levels of anti-BP180 IgG are a disease hallmark of BP, which is considered a 240 
blistering and not a lichenoid skin disease. However, it has been reported that 241 
elevated anti-BP180-IgG can be detected in certain forms of lichen planus (LP), for 242 
example vulvar LP and oral LP,23, 24 and in overlap forms, such as bullous LP and LP 243 
pemphigoides.25-27 Furthermore, BP can clinically and histologically present with a 244 




years.25-28 It is feasible that anti-BP180 IgG at low serum levels and disinhibition 246 
through anti-PD1/PD-L1 therapy could initiate a very mild presentation of BP, as 247 
opposed to the better known full blistering BP that is associated with high anti-BP180 248 
IgG titers. Our data, therefore, do not suggest that autoantibodies against BP180 249 
have a causative role but rather serve as markers for BP180 overexpression in 250 
NSCLC tissue. Why BP180 is so strongly associated with those outcomes remains 251 
to be elucidated. The expression of BP180 in tumor tissue has been shown to hold 252 
an important role in the maintenance of T-cell effector function against melanoma 253 
during ICI therapy.29 It is possible that BP180 expression in tumor tissue may hold a 254 
similar role. 255 
A limitation of our study is the restricted cohort size of 40 patients from a single 256 
center. However, identifying significant associations despite the limited size may 257 
further merit the value of our findings. Another limitation is the overall low levels of 258 
autoantibodies that can present a challenge to clinical application. We recommend 259 





In a cohort of 40 patients with NSCLC receiving ICIs we demonstrate that the pre-262 
existing levels of anti-BP180 IgG may serve as a predictive biomarker for better 263 
therapy response, prolonged OS and the development of skin irAEs during 264 
treatment. These results encourage further investigations into the role of 265 




Abbreviations and Acronyms 267 
BP: Bullous pemphigoid 268 
BP180: Bullous pemphigoid antigen 180 269 
BP230: Bullous pemphigoid antigen 230 270 
CTCAE: Common Terminology Criteria for Adverse Events 271 
EKOS: Ethics Commission of Eastern Switzerland (Ethikkommission Ostschweiz) 272 
GTEx: Genotype-Tissue Expression project (https://gtexportal.org) 273 
ICIs: Immune checkpoint inhibitors 274 
irAE: immune-related adverse event 275 
LP: Lichen planus 276 
NSCLC: Non-small cell lung cancer 277 
OS: Overall survival 278 
PD1: Progammed cell death protein 1 279 
PD-L1: Programmed death-ligand 1 280 





symbol Description / Synonym 
% SCC  
(N = 551) 
% AC 
(N = 594) 
% total 
(N = 1145) 
LAMB3 laminin subunit beta 3 86 81.6 83.7 
TGM2 (tissue) transglutaminase 2 40.8 79.3 60.8 
LAMC1 laminin subunit gamma 1 56.1 45.6 50.7 
DSC3 desmocollin 3 59 1 28.9 
COL17A1 BP180 46.1 8.9 26.8 
PPL periplakin 25.6 19.4 22.4 
COL7A1 type VII collagen alpha 1 chain 33.9 0.8 16.7 
SERPINB3 serpin family B member 3 29.6 2.7 15.6 
EVPL envoplakin 10.2 12.8 11.5 
DST BP230 6 1.2 3.5 
Table 1: Skin genes most expressed in NSCLC tissue, with BP180, BP230 and type VII collagen (all in bold) ranking among them. 282 
Abbreviations: SCC (squamous cell carcinoma subtype of non-small cell lung cancer), AC (adenocarcinoma subtype of non-small 283 





Anti-BP180 IgG Anti-BP230 IgG Anti-Coll. VII IgG 
High Low P value High Low P value High Low P value 
Responsea N (%) 
 Yes 19 (48) 11 (58) 8 (42) 
.049 
6 (32) 13 (68) 
.236 
5 (26) 14 (74) 
.047 
 No 17 (43) 4 (24) 13 (77) 2 (12) 15 (88) 0 (0) 17 (100) 
 Unknown 4 (10) 2 (50) 2 (50) 
 
2 (50) 2 (50) 
 
0 (0) 4 (100) 
 
irAE 
 Yes 25 (63) 13 (52) 12 (48) 
.187 
6 (24) 19 (76) 
1.00 
2 (8) 23 (92) 
.345 
 No 15 (38) 4 (27) 11 (73) 4 (27) 11 (73) 3 (20) 12 (80) 
 Skin irAEs 16 (40) 
 
 Rash 9 (23) 5 (56) 4 (44) .456 2 (22) 7 (78) 1.00 1 (11) 8 (89) 1.00 
 Pruritus 7 (18) 5 (71) 2 (29) .113 2 (29) 5 (71) 1.00 0 (0) 7 (100) .565 
 Other irAEs 16 (40) 
 
 Thyroiditis 6 (15) 3 (50) 3 (50) 1.00 3 (50) 3 (50) .153 1 (17) 5 (83) 1.00 
 Pneumonitis 3 (8) 1 (33) 2 (67) 1.00 1 (33) 2 (67) 1.00 1 (33) 2 (67) .338 




Table 2: Outcomes of patients with non-small cell lung cancer receiving checkpoint inhibitor therapy with high and low autoantibody 285 
levels. 286 
ELISA was measured with MESACUP anti-Skin profile kit, MBL, Nagoya, Japan. 287 
Cut-off value for high/low IgG is 8.06 U/ml, which represents the cut-off value for overall survival using maximally selected log-rank 288 
statistics for anti-BP180 IgG. 289 
aResponse: defined by complete or partial response at 3 months in the CT scan. Stable or progressive disease after 3 months in 290 
the CT scan equals no response. 291 
Percentages may not add up to 100% due to rounding. 292 
Abbreviations: Anti-Coll. VII IgG (Anti-type VII collagen IgG), irAE (immune-related adverse event 293 
 Hepatitis 3 (8) 1 (33) 2 (67) 1.00 0 (0) 3 (100) .559 0 (0) 3 (100) 1.00 
 Arthritis 1 (3) 1 (100) 0 (0) .425 1 (100) 0 (0) .250 0 (0) 0 (0) 1.00 
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Figure legends 385 
 386 
Figure 1. Skin antigen expression in non-small cell lung cancer. 387 
A, Molecular tissue fingerprinting of 1.145 non-small cell lung cancer RNA-388 
sequencing samples reveals the 10 most expressed genes of non-small cell lung 389 
cancer (NSCLC) and skin tissue (listed in Table 1). Red signifies overexpression, 390 
blue lower expression, color intensity correlates with level of expression (more 391 
intense = higher level). Sequencing data from NSCLCs were obtained from The 392 
Cancer Genome Project (https://portal.gdc.cancer.gov) and of skin tissue from the 393 
Genotype Tissue Expression (GTEx) project (https://gtexportal.org). 394 
 395 
Figure 2. Anti-skin IgG and clinical outcome parameters 396 
Top panel: Only anti-BP180 IgG correlate with overall survival (OS; Kaplan-Meier 397 
curve, *P = .04), therapy response (*P = .01, upper right box plot) and development 398 
of skin immune-related adverse events (*P = .04, middle box plot). Middle and 399 
bottom panel: Neither anti-BP230 IgG, nor anti-type VII collagen IgG correspond with 400 
OS, therapy response, the development of skin irAEs or all irAEs. IrAEs were 401 
calculated with N = 40 and OS with N = 39, since one patient was lost to follow-up. 402 
Therapy response was calculated with N = 36, as response data was not available 403 
from 4 patients. Cut-off values for high/low IgG were calculated for OS using the 404 
maximally selected log-rank statistics: Anti-BP180 IgG: 8.06 U/ml, anti-BP230 IgG: 405 
6.87 U/ml, anti-type VII collagen IgG: 3.35 U/ml. The y-axes of the box plots indicate 406 
IgG titers. Abbreviations: irAE, immune-related adverse event; HR, hazard ratio; 407 
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Log−rank P = .31
HR (low vs high) = 1.97 (0.522−7.42)
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Log−rank: P = 0.23
HR (low vs high) = 2.5 (0.539−11.6)
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